HRP20190343T1 - Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata - Google Patents

Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata Download PDF

Info

Publication number
HRP20190343T1
HRP20190343T1 HRP20190343TT HRP20190343T HRP20190343T1 HR P20190343 T1 HRP20190343 T1 HR P20190343T1 HR P20190343T T HRP20190343T T HR P20190343TT HR P20190343 T HRP20190343 T HR P20190343T HR P20190343 T1 HRP20190343 T1 HR P20190343T1
Authority
HR
Croatia
Prior art keywords
disorders
compound
pharmaceutical composition
disease
condition
Prior art date
Application number
HRP20190343TT
Other languages
English (en)
Croatian (hr)
Inventor
Delphine CHARVIN
Baptiste Manteau
Vincent Pomel
François CONQUET
Original Assignee
Prexton Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prexton Therapeutics Sa filed Critical Prexton Therapeutics Sa
Publication of HRP20190343T1 publication Critical patent/HRP20190343T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20190343TT 2014-08-27 2015-08-27 Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata HRP20190343T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182468 2014-08-27
EP15770814.0A EP3186257B1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
PCT/EP2015/069601 WO2016030444A1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Publications (1)

Publication Number Publication Date
HRP20190343T1 true HRP20190343T1 (hr) 2019-05-31

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190343TT HRP20190343T1 (hr) 2014-08-27 2015-08-27 Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata

Country Status (26)

Country Link
US (3) US10017521B2 (enExample)
EP (3) EP3502115A1 (enExample)
JP (1) JP6430015B2 (enExample)
KR (1) KR101870589B1 (enExample)
CN (2) CN106715444B (enExample)
AU (1) AU2015308438B2 (enExample)
CA (1) CA2956191C (enExample)
CY (1) CY1121352T1 (enExample)
DK (1) DK3186257T3 (enExample)
ES (1) ES2714073T3 (enExample)
HR (1) HRP20190343T1 (enExample)
HU (1) HUE041941T2 (enExample)
IL (1) IL250287B (enExample)
LT (1) LT3186257T (enExample)
MA (3) MA40530A (enExample)
ME (1) ME03339B (enExample)
MX (1) MX369643B (enExample)
NZ (1) NZ728853A (enExample)
PL (1) PL3186257T3 (enExample)
PT (1) PT3186257T (enExample)
RS (1) RS58592B1 (enExample)
RU (1) RU2672569C2 (enExample)
SI (1) SI3186257T1 (enExample)
SM (1) SMT201900152T1 (enExample)
TR (1) TR201903332T4 (enExample)
WO (1) WO2016030444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3186257T1 (sl) * 2014-08-27 2019-07-31 Prexton Therapeutics Sa Novi derivat kromon oksima in njegova uporaba kot alosterični modulator metabotropnih glutamatnih receptorjev
US10532057B2 (en) * 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
JP7633676B2 (ja) 2018-07-26 2025-02-20 ドメイン・セラピューティクス 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) * 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
US7547794B2 (en) 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20070027216A1 (en) 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
WO2009010455A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
JP5806672B2 (ja) * 2009-10-30 2015-11-10 ドメイン・セラピューティクス 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用
CN104193761B (zh) * 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
WO2013107862A1 (en) * 2012-01-18 2013-07-25 Addex Pharma S.A. NOVEL 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
SI3186257T1 (sl) * 2014-08-27 2019-07-31 Prexton Therapeutics Sa Novi derivat kromon oksima in njegova uporaba kot alosterični modulator metabotropnih glutamatnih receptorjev
US10532057B2 (en) 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia

Also Published As

Publication number Publication date
EP3186257B1 (en) 2019-02-06
US10442818B2 (en) 2019-10-15
IL250287A0 (en) 2017-03-30
MA48048A (fr) 2020-02-12
MA40530A (fr) 2017-07-05
SMT201900152T1 (it) 2019-05-10
KR101870589B1 (ko) 2018-06-25
US20180291034A1 (en) 2018-10-11
CY1121352T1 (el) 2020-05-29
CN106715444B (zh) 2019-07-12
LT3186257T (lt) 2019-04-25
TR201903332T4 (tr) 2019-03-21
CA2956191C (en) 2020-01-28
CA2956191A1 (en) 2016-03-03
NZ728853A (en) 2018-04-27
RU2672569C2 (ru) 2018-11-16
JP2017525776A (ja) 2017-09-07
ES2714073T3 (es) 2019-05-27
CN110343118A (zh) 2019-10-18
SI3186257T1 (sl) 2019-07-31
JP6430015B2 (ja) 2018-11-28
AU2015308438B2 (en) 2018-12-13
AU2015308438A1 (en) 2017-03-02
IL250287B (en) 2020-02-27
RU2017109818A (ru) 2018-10-01
PT3186257T (pt) 2019-03-27
HUE041941T2 (hu) 2019-06-28
PL3186257T3 (pl) 2019-07-31
EP3502115A1 (en) 2019-06-26
MA52702A (fr) 2021-03-31
EP3186257A1 (en) 2017-07-05
MX2017002429A (es) 2017-08-02
DK3186257T3 (en) 2019-04-01
US20170253613A1 (en) 2017-09-07
US20200024285A1 (en) 2020-01-23
RU2017109818A3 (enExample) 2018-10-01
ME03339B (me) 2019-10-20
EP3696183A1 (en) 2020-08-19
KR20170042624A (ko) 2017-04-19
CN106715444A (zh) 2017-05-24
US10017521B2 (en) 2018-07-10
WO2016030444A1 (en) 2016-03-03
MX369643B (es) 2019-11-15
RS58592B1 (sr) 2019-05-31

Similar Documents

Publication Publication Date Title
DOP2016000273A (es) Compuesto de ciclopropanamina y sus usos.
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
EP3600563C0 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING VITAMIN D3 AND HYALURONIC ACID
CL2018003105A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
BR112018010018A2 (pt) moduladores de ror-gama
ECSP16070327A (es) Heteroaril amidas como inhibidores de agregación de proteína
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
BR112016004505A2 (pt) uso de uma combinação de pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos, uso de pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos, e uso de uma composição compreendendo pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos
CO2019007830A2 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas
CR20160310A (es) Composiciones farmacpeuticas que comprenden azd9291
CO6270332A2 (es) Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
BR112014005810A2 (pt) formas sólidas de um inibidor da dissociação de transtirretina
CL2019001752A1 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas.
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
HRP20190343T1 (hr) Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112017025427A2 (pt) composição farmacêutica oral
CO2019007833A2 (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
PL2722322T3 (pl) 1,3-Di-okso-indenowa pochodna, jej farmaceutycznie dopuszczalna sól lub izomer optyczny, sposób jej wytwarzania i kompozycja farmaceutyczna ją zawierająca jako przeciwwirusowy składnik czynny
JP2017525776A5 (enExample)
BR112018012616A2 (pt) formulação galênica que compreende um fármaco tópico
BR112018002138A2 (pt) composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões
CO2020013561A2 (es) Nueva sal de cisteamina para la preparación de partículas altamente inhalables